TNF and rheumatoid arthritis: Two retrospective cohort studies [15,21] showed that anti-TNF therapy is not associated with an increased risk for new or recurrent cancer (crude incident cancer rates 42 and 34.5 per 1000 PY, respectively), in agreement with a study of anti-TNF agents in patients with rheumatoid arthritis [51,52].